多家跨机构研究表明，在2019年新型冠状病毒肺炎（COVID-19）疫情期间诊断为黑色素瘤的患者呈现出更为晚期的黑色素瘤。为了进一步描述COVID-19疫情期间被诊断为黑色素瘤的患者特征，本研究回顾性地基于Surveillance, Epidemiology, and End-Results（SEER）登记数据对2018年至2020年间被诊断为皮肤黑色素瘤的患者进行了人群基础队列研究。尽管治疗延迟较少，但在2020年被诊断为黑色素瘤的患者更有可能出现增加的Breslow深度、更多的溃疡、结节性肿瘤以及更为晚期的诊断阶段。患者往往来自较为富裕、城市化程度较高的地区，并且原发外科治疗更有可能选用莫氏手术。2020年的诊断与整体或疾病特定存活率无相关性。本研究是一项回顾性队列回顾性和具有短期随访时间，这可能会影响生存结果。与以往年份相比，2020年黑色素瘤的诊断人数下降了15.5%，这可能与延迟就诊有关。2020年被诊断为黑色素瘤的患者往往具有更厚的、更溃疡的和更为晚期的肿瘤，但这与生存率无关。需要进一步研究来描述COVID-19疫情期间被诊断为黑色素瘤的患者的预后。版权所有 © 2023，Elsevier Inc. 发表。

Prior multi-institutional studies demonstrate that patients diagnosed with melanoma during the Coronavirus Disease 2019 (COVID-19) pandemic presented with more advanced melanomas.To further characterize patients diagnosed with melanoma during the COVID-19 pandemic.Retrospective population-based cohort study of the Surveillance, Epidemiology, and End-Results (SEER) registry of patients diagnosed with cutaneous melanoma from 2018-2020.Patients diagnosed with melanoma in 2020 were more likely to have increased Breslow depth, more ulceration, nodular tumors, and more advanced stage at diagnosis despite less treatment delays. Patients tended to be from wealthier, more urban areas. Primary surgical treatment was more likely to be with Mohs surgery. Diagnosis in the year 2020 was not correlated with overall or disease specific survival.This is a retrospective cohort review and limited by short follow-up times, which could affect survival outcomes. There was a 15.5% drop in melanoma diagnosis in 2020 compared to prior years, which could relate to delayed presentation.Patients diagnosed with melanoma in 2020 tended to have thicker, more ulcerated, and more advanced tumors, but this was not associated with survival. Further studies are needed to characterize outcomes for patients diagnosed with melanoma during the COVID-19 pandemic.Copyright © 2023. Published by Elsevier Inc.